<DOC>
	<DOCNO>NCT00020904</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness BMS-247550 treat woman stage IV recurrent metastatic breast cancer .</brief_summary>
	<brief_title>BMS-247550 Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical activity BMS-247550 , term tumor response rate , woman taxane-resistant metastatic breast cancer . - Determine safety drug patient . - Determine duration response , time progression , survival patient treat drug . OUTLINE : This multicenter study . Patients receive BMS-247550 IV 3 hour day 1 . Treatment continue every 3 week 4-18 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 4 additional course beyond CR . Responding patient may receive additional course investigator 's discretion . Patients follow every 3 month . PROJECTED ACCRUAL : A total 14-50 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic breast carcinoma Stage IV recurrent disease distant metastases Most recent prior chemotherapy docetaxelbased paclitaxelbased therapy metastatic disease Progressed therapy within 4 month last dose OR Progressed therapy within 6 month last dose give adjuvant treatment Received prior anthracycline therapy Bidimensionally measurable metastatic lesion Bony lesion consider measurable No known brain metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Sex : Female Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 2,000/mm^3 Platelet count great 125,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 2.5 time ULN ( 5 time ULN hepatic metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina , myocardial infarction , congestive heart failure within past 6 month Other : No grade 2 great neuropathy ( motor sensory ) No uncontrolled infection medical illness would preclude study No psychiatric disorder condition would preclude study No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No hypersensitivity agent contain Cremophor EL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 24 hour since prior growth factor No concurrent trastuzumab ( Herceptin ) No concurrent immunotherapy Chemotherapy : See Disease Characteristics No 1 prior chemotherapy regimen metastatic disease except anthracyclinecontaining regimen firstline therapy taxane secondline therapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy ( except hormone replacement therapy ) Radiotherapy : At least 3 week since prior radiotherapy , except palliative radiotherapy le 20 % bone marrow , recover No prior radiotherapy major bone marrowcontaining area ( pelvis lumbar spine ) No prior radiotherapy target lesion measurable lesion No concurrent therapeutic radiotherapy Surgery : At least 1 week since prior minor surgery At least 3 week since prior major surgery Recovered prior surgery Other : Recovered prior treatmentrelated toxic effect ( alopecia allow ) No concurrent experimental anticancer medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>